معرفی
Junwei Shi, Ph.D., serves as Associate Professor of Cancer Biology at the University of Pennsylvania's Perelman School of Medicine. He holds dual appointments as Assistant Investigator at the Abramson Family Cancer Research Institute and Core Member of the Epigenetics Institute, focusing on CRISPR-based functional genomics to dissect leukemia vulnerabilities.
- B.S. in Biotechnology, Sun Yat-sen University (China), 2008
- Ph.D. in Molecular and Cellular Biology, Stony Brook University, SUNY, 2016
Dr. Shi's research centers on identifying epigenetic and transcriptional dependencies in leukemia using domain-focused CRISPR screening. His lab pioneers AsCas12a-based multiplex screening tools to investigate protein domain functions and develop novel therapeutic targets. Key areas include epigenetic regulator dependencies in leukemia, CRISPR tool development for combinatorial chromatin perturbations, and dissecting genetic regulatory pathways driving cancer maintenance through functional genomics approaches.
Analysis of recent publications reveals a strong emphasis on CRISPR screening to uncover leukemia-specific vulnerabilities (40%), T cell exhaustion mechanisms in immunotherapy (30%), and epigenetic/hemoglobin regulation (20%). His work bridges basic cancer biology with translational applications, particularly in acute myeloid leukemia and T cell engineering.
Dr. Shi actively mentors graduate students and postdoctoral researchers, with current advisees including six Ph.D. students and multiple postdocs. His lab receives funding from institutional sources including the Abramson Family Cancer Research Institute and the Epigenetics Institute, though specific grant details are not publicly enumerated.
The Shi Lab maintains a 10-member research team focused on CRISPR screening development and leukemia biology, operating within the Cancer Biology Department's state-of-the-art facilities at the University of Pennsylvania.
